(Press-News.org) A type of drug used to treat diabetes may reduce the risk of developing Parkinson's disease, according to a new study published in PLOS Medicine.
The research, led by the London School of Hygiene & Tropical Medicine, found that diabetes patients taking glitazone antidiabetes drugs (either rosiglitazone or pioglitazone) had a 28% lower incidence of Parkinson's disease than people taking other treatments for diabetes who had never taken glitazones. [1]
Glitazones are a class of drug that activate the peroxisome proliferation-activated gamma (PPARγ) receptor, which is found inside cells in many different body organs. PPARγ activation by glitazones leads to reduced insulin resistance, which has been useful for treating people with diabetes, but the receptor has many other functions that have not been studied as thoroughly in humans.
Although the potential effect of glitazones on Parkinson's disease had previously been demonstrated in rodents and in vitro, the authors believe this is the first study to show the relationship between glitazone use and incidence of Parkinson's disease in humans. [2]
The study, which was funded by The Michael J Fox Foundation for Parkinson's Research, looked at more than 160,000 diabetes patients in the UK. Researchers used electronic health records from the UK Clinical Practice Research Datalink to match 44,597 glitazone users with 120,373 people using other antidiabetic drugs. Glitazone users were matched by age, sex, GP practice, and diabetes treatment stage with up to five users of other diabetic treatments.
Patients were followed up from 1999 (when glitazones were introduced to treat diabetes) until 2013, to determine how many were diagnosed with Parkinson's disease during that period.
The results showed a 28% reduction in incidence of Parkinson's disease among people taking glitazones compared with those taking other antidiabetic treatments. Adjustments for risk factors associated with Parkinson's disease (including smoking and head injury) had no impact on the findings.
The results suggest that the reduced risk of Parkinson's disease was only associated with current treatment with glitazones, and that there is little or no longer lasting benefit if people have taken the drug in the past before stopping or switching to another medication.
Senior author Dr Ian Douglas from the London School of Hygiene & Tropical Medicine said: "We often hear about negative side effects associated with medications, but sometimes there can also be unintended beneficial effects.
"Our findings provide unique evidence that we hope will drive further investigation into potential drug treatments for Parkinson's disease. It's thought that around one in 500 people are affected by Parkinson's, and to date no effective treatments have been found to directly tackle the neurodegenerative aspect of the disease."
Dr Ruth Brauer, who worked on the study while at the London School of Hygiene & Tropical Medicine, [3] said: "Our results suggest that treatments which activate the PPARγ receptor in the same way as glitazones could be promising targets in future drug research. Although our study only looked at people with diabetes, we believe it's likely that the protective effect of glitazones may also be seen in people without diabetes."
The authors note that their study only included patients with diabetes who had not been diagnosed with Parkinson's disease when they started taking glitazones, and therefore they cannot establish whether taking the drug slows or prevents the progression of the disease. They also highlight that glitazones have been associated with some serious side effects. [4]
INFORMATION:
The study was carried out in collaboration with researchers at UCL and Imperial College London.
For more information or to request interviews contact the London School of Hygiene & Tropical Medicine press office on press@lshtm.ac.uk or +44(0)2079272802.
Notes to Editors:
Ruth Brauer, Krishnan Bhaskaran, Nishi Chaturvedi, David T Dexter, Liam Smeeth, Ian Douglas, Glitazone treatment and incidence of Parkinson's disease among people with diabetes: a retrospective cohort study, PLOS Medicine. DOI: 10.1371/journal.pmed.1001854
Link once paper goes live: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001854
[1] An incidence rate ratio (IRR) was calculated using conditional Poisson regression, adjusted for possible confounders. The incidence rate of Parkinson's disease in the glitazone-using group was 6.4 per 10,000 patient years compared with 8.8 per 10,000 patient years in users of other antidiabetic treatments (IRR 0.72, 95% CI 0.60-0.87).
[2] The authors believe their study is the first population-based investigation of the relationship between treatment with glitazone drugs and the incidence of Parkinson's disease. A recently published clinical trial into the effect of pioglitazone on the progression of Parkinson's disease suggested that pioglitazone at the doses studied is unlikely to modify progression in early Parkinson's disease. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial, The Lancet Neurology, DOI: http://dx.doi.org/10.1016/S1474-4422(15)00144-1
[3] Dr Ruth Brauer is now at King's College London.
[4] Rosiglitazone was introduced to the market in 1999, but was eventually suspended due to cardiovascular safety concerns. However, late 2013 the FDA removed the prescribing and dispensing restrictions for rosiglitazone medicines that were put into place in 2010. Whilst pioglitazone use has waned due to concerns over the risk of bladder cancer, recent studies show that the association may be partly mediated by proteinuria testing.
VANCOUVER, B.C. and DURHAM, N.C. - A Phase III, individually randomized trial has found conditional cash transfers for school attendance did not reduce the risk of HIV among high-school aged women in South Africa, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada.
The new finding is from HPTN 068, the first individually randomized study of young women conditioned on school attendance with an HIV incidence endpoint. In the trial, ...
An international panel of leading scientists is launching a new TripAdvisor-style website aimed at helping researchers choose better-quality research tools - and avoiding potentially serious errors in biomedical research.
In a 'call to action' published today (Tuesday), the international expert panel warns that many scientists are unwittingly using poor-quality chemical probes, leading to mistaken conclusions being drawn from research studies.
The expert panel - made up of researchers from non-profit research institutions and from biotechnology and pharmaceutical companies ...
July 2, 2015 - Porcine reproductive and respiratory syndrome virus (PRRSV) is the most widespread disease in the swine industry. In sows, PRRSV causes reproductive problems during gestation, including abnormal litters or abortions. Growing pigs with the disease will have respiratory problems and poor growth.
In 2012, Holtkamp and colleagues estimated the annual losses due to PRRSV to be a staggering $664 million in the U.S. alone. Producers on larger farms use vaccines and enhanced biosecurity measures to prevent eradicating an entire herd during a PRRSV outbreak. Unfortunately, ...
NEW YORK, July 21, 2015 -- A recent study conducted at Nathan S. Kline Institute for Psychiatric Research (NKI) and NYU Langone Medical Center implicates a new culprit in Alzheimer's disease development. The research reveals that ßCTF -- the precursor of the amyloid beta (Aß) peptide -- acts at the earliest stage of Alzheimer's to initiate a range of abnormalities leading to the loss of groups of neurons critical for memory formation. Results from the study are published online July 21, 2015 in the journal, Molecular Psychiatry, and the article has been selected ...
WASHINGTON -- In animal models, acupuncture appears to impact the same biologic pathways ramped up by pain and stress, analogous to what drugs do in humans. Georgetown University Medical Center (GUMC) researchers say their animal study, published online in Endocrinology, provides the strongest evidence to date on the mechanism of this ancient Chinese therapy in chronic stress.
"The benefits of acupuncture are well known by those who use it, but such proof is anecdotal. This research, the culmination of a number of studies, demonstrates how acupuncture might work in the ...
Electroconvulsive therapy remains one of the most effective treatments for severe depression, but new UNSW research shows ultra-brief pulse stimulation is almost as effective as standard ECT, with far fewer cognitive side effects.
The study, published today in the Journal of Clinical Psychiatry, is the first systematic review to examine the effectiveness and cognitive effects of standard ECT treatment, brief pulse stimulation, versus the newer treatment, known as ultra-brief pulse right unilateral (RUL) ECT.
It comes after previous trials had shown conflicting results. ...
Native Americans living in the Amazon bear an unexpected genetic connection to indigenous people in Australasia, suggesting a previously unknown wave of migration to the Americas thousands of years ago, a new study has found.
"It's incredibly surprising," said David Reich, Harvard Medical School professor of genetics and senior author of the study. "There's a strong working model in archaeology and genetics, of which I have been a proponent, that most Native Americans today extend from a single pulse of expansion south of the ice sheets--and that's wrong. We missed something ...
There is archaeological evidence of modern humans in the Americas by ca. 15 thousand years ago (KYA). However, there is still debate over exactly when and how many times the ancestors of present-day Native Americans entered the New World from Siberia. A large genome-scale study conducted by an international team headed by the Centre for GeoGenetics at the University of Copenhagen has now provided answers to these questions. The study reveals that the ancestors of all present-day Native Americans arrived in the Americas as part of a single migration wave, no earlier than ...
Location-based advertisements may pinpoint customers geographically, but often miss the target because customers may find the ads creepy and intrusive, according to an international team of researchers. To overcome this negativity, the researchers suggest advertisers invite their customers to help tailor ads they might receive.
While being physically close to a product or shop improved attitudes about local advertisements on their mobile devices, customers felt significantly better about both the advertisement and location-based advertising when they had a hand in selecting ...
Emergency room physicians treating patients with alcohol-related trauma can better identify those at risk of future drinking-related trauma with a 10-point questionnaire rather than the standard blood alcohol content test, according to a study in The Journal of the American Osteopathic Association (JAOA).
The questionnaire, known as the Alcohol Use Disorders Identification Test (AUDIT), was developed by the World Health Organization to address difficulties in identifying at-risk drinking behavior. It assesses alcohol consumption, drinking behaviors and alcohol-related ...
